A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

✍ Scribed by Osama E. Rahma; Ed Ashtar; Malgorzata Czystowska; Marta E. Szajnik; Eva Wieckowski; Sarah Bernstein; Vincent E. Herrin; Mortada A. Shams; Seth M. Steinberg; Maria Merino; William Gooding; Carmen Visus; Albert B. DeLeo; Judith K. Wolf; Jeffrey G. Bell; Jay A. Berzofsky; Theresa L. Whiteside; Samir N. Khleif

• Publisher: Springer-Verlag
• Year: 2011
• Tongue: English
• Weight: 529 KB
• Volume: 61
• Category: Article
• ISSN: 0340-7004
• DOI: 10.1007/s00262-011-1100-9